Humira number of patents evergreening?

Short answer: there isn’t a single fixed number. “Evergreening” patents for Humira isn’t a discrete count; it’s a large, evolving portfolio built up over many years across multiple jurisdictions. Humira (adalimumab) is widely described as one of the most patent-rich biologics, with a web of patents around the molecule, its manufacturing, formulations, devices for delivery, and various methods of use.

rough points you can rely on:
- United States: public reports have described the Humira patent family as comprising dozens of granted US patents (roughly in the tens, e.g., 40–70 in different years), with many continuations and related family members. The exact count depends on whether you include continuations, divisionals, and related device/formulation patents.
- Worldwide: far more patents exist when you count all countries; the global portfolio is often described as hundreds of patents and patent families in many jurisdictions.
- Categories often used to extend protection: composition/molecule patents, manufacturing process improvements, formulation and delivery (including auto-injector devices), dosing and administration methods, and various method-of-use patents.

If you want a precise current number, I can help you pull it from patent databases. Tell me:
- US-only or global?
- Do you want only granted patents, or also pending applications?
- Include device/formulation patents or only molecule-related patents?

I can then outline the latest landscape with sources.